The Lancet Oncology
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma
A Phase I Study of the First-in-Class Antimitochondrial
Metabolism Agent,CPI-613, in Patients with Advanced
Hematologic Malignancies
Lipoic acid and lipoic acid analogs in cancer metabolism and chemotherapy
A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process
Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo
We are who we have always been - an organization dedicated to addressing significant unmet needs with therapies for rare cancers. We've returned to our company roots with our original company name. Now, more than ever, we want our patients to know how committed we are to developing treatments for rare cancers. And that is exactly what Cornerstone represents.